Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRK2 | P25098 | 8/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CFTR | P13569 | 1/20 | 0.53 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.52 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690273 | 1.00 | GRK2 (0.65) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL3631238 | 0.89 | GRK2 (0.55) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL3631239 | 0.89 | GRK2 (0.55) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL14082228 | 0.89 | GRK2 (0.63) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL3631996 | 0.88 | KMT2A (0.54) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL3631995 | 0.88 | KMT2A (0.54) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL1669192 | 0.88 | GRK2 (0.55) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL1669195 | 0.88 | GRK2 (0.55) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL1669778 | 0.88 | GRK2 (0.67) | GRK2ROCK2MEN1KMT2AMAPT | |
| SCHEMBL1669780 | 0.88 | GRK2 (0.67) | GRK2ROCK2MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | claimed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283351-B2 | Inhibiting cyctic fibrosis transmembrane conductance regulator polypeptide ; therapy for diarrhea and polycystic kidney disease | INSTITUTE FOR ONEWORLD HEALTH (US) | 2012-10-09 | — | — | US | disclosed |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH | 2012-05-31 | — | — | US | disclosed |
| EP-2421528-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | Institute for OneWorld Health (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-05-19 | — | — | US | disclosed |
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | disclosed |
| US-7888332-B2 | Hydrazide-containing CFTR inhibitor compounds and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-02-15 | — | — | US | disclosed |
| WO-2010123933-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2010-10-28 | — | — | WO | disclosed |
| EP-2142498-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | Institute for Oneworld Health (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-02-19 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH | 2008-10-30 | — | — | US | disclosed |
| WO-2008121877-A2 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | INSTITUTE FOR ONEWORLD HEALTH (US) | 2008-10-09 | — | — | WO | disclosed |
| US-7414037-B2 | cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-19 | — | — | US | disclosed |
| US-7414037-B2 | cystic fibrosis transmembrane conductance regulator protein inhibitor; 2-naphthalenylamino-[(3,5-dibromo-2,4-dihydroxyphenyl)methylene][3-[4-(3-(PEG)n-thioureido)diphenyl)-thioureido]propanedioic acid dihydrazide (MalH-(PEG)nB); cystic fibrosis with forms of male infertility, secretory diarrhea | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110119775-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | GRK2 1951/4885ROCK2 3569/4885MEN1 3964/4885 |
| US-20120136003-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING 1,3,4-OXADIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | GRK2 892/4885ROCK2 2407/4885MEN1 2771/4885 |
| US-20080269206-A1 | CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, PKD1, PKD2 | GRK2 1560/4885ROCK2 2423/4885MEN1 2759/4885 |
| US-20090048207-A1 | HYDRAZIDE-CONTAINING CFTR INHIBITOR COMPOUNDS AND USES THEREOF | CFTR, ABCC5, SLC9A5 | GRK2 1951/4885ROCK2 3569/4885MEN1 3964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.